<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thoracic <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> is a major health problem with multiple etiologies and potentially devastating consequences </plain></SENT>
<SENT sid="1" pm="."><plain>Currently, no large randomized trial has shown that medical therapy can significantly slow or halt the progressive <z:mpath ids='MPATH_66'>dilatation</z:mpath> that eventually leads to dissection and rupture </plain></SENT>
<SENT sid="2" pm="."><plain>A recent study that suggested that angiotensin receptor blocking agents slow the development of <z:hpo ids='HP_0002617'>aneurysm</z:hpo> <z:mpath ids='MPATH_66'>dilatation</z:mpath> in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> has revived interest in medical interventions to improve outcomes for patients with <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In this article, we review the available data on established medical therapies and investigational medical therapies for thoracic <z:hpo ids='HP_0004942'>aortic aneurysms</z:hpo> </plain></SENT>
</text></document>